SCHEMBL1482797

SCHEMBL1482797

N#Cc1cccc(COc2cc(Cl)ccc2-c2nc3cc(F)c(F)cc3n2CC2CCCCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.43
SLC6A4 P31645 1/20 0.43
NR1H4 Q96RI1 2/20 0.43
ALOX5 P09917 2/20 0.40
VDR P11473 1/20 0.38
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
HTR6 P50406 2/20 0.37
PDCD1 Q15116 3/20 0.36
CD274 Q9NZQ7 3/20 0.36
CTSL P07711 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
MET P08581 1/20 0.36
CNR2 P34972 1/20 0.36
GRM5 P41594 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
CCR2 P41597 1/20 0.35
TDP2 O95551 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482444 0.91 NR1H4 (0.45) SLC6A4NR1H4ALOX5VDRCTSL
SCHEMBL1482691 0.88 NR1H4 (0.44) SLC6A4NR1H4ALOX5VDRCTSL
SCHEMBL1482050 0.88 NR1H4 (0.44) SLC6A4NR1H4ALOX5VDRCTSL
SCHEMBL1484274 0.88 CCR2 (0.42) MRGPRX4SLC6A4NR1H4ALOX5APCCR2
SCHEMBL1482276 0.87 NR1H4 (0.43) SLC6A4NR1H4ALOX5VDR
SCHEMBL1482189 0.85 NR1H4 (0.42) SLC6A4NR1H4ALOX5VDRCTSL
SCHEMBL1482456 0.85 MRGPRX4 (0.49) MRGPRX4NR1H4VDR
SCHEMBL1482661 0.85 NR1H4 (0.44) SLC6A4NR1H4ALOX5VDRCTSL
SCHEMBL1482669 0.85 NR1H4 (0.41) SLC6A4NR1H4ALOX5VDRCTSL
SCHEMBL1482100 0.84 NR1H4 (0.50) SLC6A4NR1H4ALOX5VDRHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 MRGPRX4 650/4885SLC6A4 2832/4885NR1H4 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.